OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Danilov on the Efficacy of the Combination Zandelisib and Zanubrutinib in R/R B-Cell Malignancies

August 13th 2021

Alexey V. Danilov, MD, PhD, discusses the efficacy seen in the ongoing phase 1b study examining the combination of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.

Dr. Mita on Treatment Selection in ER+, HER2- Breast Cancer

August 13th 2021

Monica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.

Dr. Basho on the Emergence of Bispecific Antibodies in HER2+ Breast Cancer

August 13th 2021

Reva K. Basho, MD, discusses the emergence of bispecific antibodies in HER2-positive breast cancer.

Dr. Sekeres on the Goal of Transfusion Independence in Higher-Risk MDS

August 12th 2021

Mikkael A. Sekeres, MD, discusses the goal of transfusion independence in higher-risk myelodysplastic syndromes.

Dr. Jamieson on the Importance of Treating at Diagnosis in Myelofibrosis

August 12th 2021

Catriona Jamieson, MD, PhD, discusses the importance of treating patients with myelofibrosis at diagnosis.

Dr. Sam on Therapeutic Developments in Metastatic HER2+ Breast Cancer

August 12th 2021

Christine Sam, MD, discusses therapeutic developments in metastatic HER2-positive breast cancer.

Dr. Chase on the Importance of Genetic Testing for BRCA Mutations in Ovarian Cancer

August 12th 2021

Dana Chase, MD, FACOG, gynecologic oncologist, discusses the importance of utilizing genetic testing for BRCA mutations in ovarian cancer.

Dr. Extermann on the Utility of Trastuzumab Monotherapy in HER2+ Breast Cancer

August 11th 2021

Martine Extermann, MD, PhD, discusses the utility of single-agent trastuzumab in HER2-positive breast cancer.

Dr. Slovin on Considerations for Treatment Selection in Nonmetastatic CRPC

August 11th 2021

Susan F. Slovin, MD, PhD, discusses considerations for treatment selection in nonmetastatic castration-resistant prostate cancer.

Dr. Thompson on the Evolving Role of MRD Testing in CLL

August 11th 2021

Meghan Thompson, MD, discusses the evolving role of minimal residual disease testing in chronic lymphocytic leukemia.

Dr. Kahl on the Emergence of Antibody-Drug Conjugates in Lymphoma

August 11th 2021

Brad S. Kahl, MD, discusses the emergence of antibody-drug conjugates in lymphoma.

Dr. Vose on Future Research Efforts With CAR T-Cell Therapy in Lymphoma

August 11th 2021

Julie M. Vose, MD, MBA, discusses future research efforts with CAR T-cell therapy in lymphoma.

Dr. Moskowitz on the Challenges of Intensifying Treatment in Hodgkin Lymphoma

August 11th 2021

Alison J. Moskowitz, MD, discusses the challenges of intensifying treatment in Hodgkin lymphoma.

Dr. Ansell on Incorporating Immunotherapies Beyond CAR T-Cell Therapy in NHL

August 11th 2021

Stephen M. Ansell, MD, PhD, discusses incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Roeker on the Rationale for BTK/Venetoclax Combos in CLL

August 10th 2021

Lindsey Roeker, MD, discusses the rationale for combining venetoclax with BTK inhibitors for use in patients with chronic lymphocytic leukemia.

Dr. Danila on Considerations for Treatment Selection in Nonmetastatic CRPC

August 10th 2021

Daniel C. Danila, MD, discusses factors to consider when selecting a treatment option for patients with nonmetastatic castration-resistant prostate cancer.

Dr. Harris on the Adoption of Immunotherapy in Advanced HCC

August 10th 2021

William P. Harris, MD, discusses the adoption of immunotherapy in advanced hepatocellular carcinoma.

Dr. Lee on the Evolving Treatment Paradigm in Relapsed/Refractory Multiple Myeloma

August 10th 2021

Hans Lee, MD, discusses the evolving treatment paradigm in relapsed/refractory multiple myeloma.

Dr. Jones on the Importance of Immune Checkpoint Inhibitors in CRC

August 10th 2021

Jeremy C. Jones, MD, discusses key lessons learned from the phase 3 KEYNOTE-177 trial.

Dr. Willmott on the Importance of Genetic Testing in Ovarian Cancer

August 9th 2021

Lyndsay Willmott, MD, discusses the importance of genetic testing in ovarian cancer.